Gossamer Bio has reported its financial results for the first quarter of 2026, revealing that the company's revenue exceeded analysts' expectations. However, the earnings per share (EPS) fell short of projections during the same period. The earnings call provided insights into the company's performance and future outlook, highlighting the factors contributing to the revenue growth and the challenges faced in achieving EPS targets.
Related Articles
Don't miss out on breaking stories and in-depth articles.